Focus: Origin is a public-stage biotech company founded in 2023 headquartered in Ruston, LA, specializing in nitric oxide-emitting devices and early-stage oncology therapeutics. The company maintains a public listing (ticker: OBK) with a diversified pipeline spanning rare metabolic diseases, oncology, and device-based treatments.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Growing — net +10 jobs in 30d
10 jobs added vs 0 removed. Steady team buildout.
Origin offers financial stability and pipeline diversity but signals execution risk through minimal hiring activity and nascent clinical stage—suitable for risk-tolerant researchers, but commercialization upside is years away.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Origin
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Origin's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo